Skip to content

The MIRROR Registry: Minimally Invasive IntRaceRebral HemORrhage Evacuation

The MIRROR Registry: Minimally Invasive IntRaceRebral HemORrhage Evacuation

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04494295
Acronym
MIRROR
Enrollment
500
Registered
2020-07-31
Start date
2020-10-23
Completion date
2029-10-15
Last updated
2026-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Supratentorial Hemorrhage

Brief summary

This registry will study the use of the Aurora® Surgiscope to provide surgical access and visualization in minimally invasive removal of hematoma in the brain. Many methods of hematoma removal are available and will be based on surgeon preference. The impact of patient selection and time to surgery from last known well time will be explored.

Interventions

DEVICEAurora Surgiscope System

MIS evacuation of hematoma using the Aurora Surgiscope System

Sponsors

Integra LifeSciences Corporation
Lead SponsorINDUSTRY
Icahn School of Medicine at Mount Sinai
CollaboratorOTHER
Oculus Imaging LLC
CollaboratorUNKNOWN

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Subject Age is \> 18 * Subject with a Head CT that demonstrates an acute, spontaneous, primary, supratentorial ICH of volume \> 20 mL, assessed via standard of care techniques * Subject Surgery can be initiated within 24 hours of the last known well time or, in patients with wake-up onset, within 24 hours of the time the patient awoke with symptoms. * Subject has a NIHSS score \> 5 * Subject has a baseline Modified Rankin Scale (mRS) Score ≤ 2 * Subject with a CT Angiography demonstrating no vascular malformation

Exclusion criteria

* Subject has an underlying vascular lesion defined as causative source of ICH * Subject has a profound neurological deficit defined as fixed/dilated pupils or bilateral extensor motor posturing * Subject has an Infratentorial or brainstem ICH * Subject has a known life expectancy \< 6 months * Subject has an uncorrectable coagulopathy * Subject has a mechanical heart valve * Subject is pregnant * Subject participates in another concurrent interventional clinical trial * Subject who is unable to meet study follow-up requirements

Design outcomes

Primary

MeasureTime frameDescription
Rate of Surgical SuccessDuring surgical procedure to evacuate supratentorial intracerebral hemorrhageRate of surgical success defined as reduction to \< 15 cc total volume of the supratentorial intracerebral hemorrhage on immediate Post-op CT Scan

Countries

United States

Contacts

CONTACTHabib Nacer-Chérif
habib.nacercherif@integralife.com+33626190029
STUDY_DIRECTORSigmund Kulessa

Integra LifeSciences Corporation

PRINCIPAL_INVESTIGATORChristopher Kellner, MD

Icahn School of Medicine at Mount Sinai

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 7, 2026